| Search by tag or site | Login to my blog ? Start my own blog |
 |
BioHealth InvestorBioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network. |
Bioveris Acquisition Underscores Importance Of Diagnostics
Posted on 04/07/2007 21:44:12 | Link | Post Comment
by Sara Calabro
Med Tech Sentinel
Roche’s (RHHBY) decision to acquire BioVeris (BIOV) for approximately $600 million, announced Wednesday and said to expand the Swiss firm’s presence in immunochemistry, underscores the growing role of diagnostic tests in today’s research environment.
The immunodiagnostic and nucleic acid testing markets are estimated at $6 billion and $1.5 billion, respectively. Already a significant player in immunochemistry, Roche through the acquisition will dominate the market. It will gain the complete patent estate of the electrochemiluminescence technology deployed in its Elecsys product line, the fastest growing portfolio of Roche Diagnostics’ lab diagnostics business. This will effectively position Roche, as the advent of simple, affordable and more accurate diagnostic products continues to alter the environment in which tests are typically performed – from clinical reference and central hospital laboratories to decentralized patient care centers and point-of-care sites.
Source: OneMedPlace.com
RELATED READING:
- Biotech Daily Review: Roche Buys BioVeris For $600M
_____________________
Med Tech Sentinel
Roche’s (RHHBY) decision to acquire BioVeris (BIOV) for approximately $600 million, announced Wednesday and said to expand the Swiss firm’s presence in immunochemistry, underscores the growing role of diagnostic tests in today’s research environment.
The immunodiagnostic and nucleic acid testing markets are estimated at $6 billion and $1.5 billion, respectively. Already a significant player in immunochemistry, Roche through the acquisition will dominate the market. It will gain the complete patent estate of the electrochemiluminescence technology deployed in its Elecsys product line, the fastest growing portfolio of Roche Diagnostics’ lab diagnostics business. This will effectively position Roche, as the advent of simple, affordable and more accurate diagnostic products continues to alter the environment in which tests are typically performed – from clinical reference and central hospital laboratories to decentralized patient care centers and point-of-care sites.
Source: OneMedPlace.com
RELATED READING:
- Biotech Daily Review: Roche Buys BioVeris For $600M
_____________________
- Mri To Lead Growth In Medical-imaging Market
- Malaria And Hiv - Eradication And Treatment
- Dragon’s New Production Process To Cut Costs
- Mrsa Update: Cepheid, Basilea And Nektar
- If Only Us Health Care Could Be More Like The Patriots (or Even The Red Sox) And Less Like The Yankees
- Millionaire Now! by Larry Nusbaum
- Ludwig von Mises Institute
- Credit Bloggers
- Don't Mess With Taxes
- Invest2Success
- Poor and Stupid
Examples
Morpheus Trading - Mon Jul 21, 2008 08:33AM
NOTE: Please click on the charts below to enlarge them if [read more]
NOTE: Please click on the charts below to enlarge them if [read more]
Morpheus Trading - Mon Jul 21, 2008 08:31AM
NOTE: Please click on the charts below to enlarge them i [read more]
NOTE: Please click on the charts below to enlarge them i [read more]
Millionaire Now! by Larry Nusbaum - Fri Jul 18, 2008 08:23AM
U.S. stock futures rebound on Citigroup results"S&a [read more]
U.S. stock futures rebound on Citigroup results"S&a [read more]
<< My Home | TheMoneyBlogs Home